These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 35278776)
21. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2. Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648 [TBL] [Abstract][Full Text] [Related]
22. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
23. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054 [TBL] [Abstract][Full Text] [Related]
25. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential VEGFR-2 inhibitors, apoptotic inducers. Elgammal WE; Halawa AH; Eissa IH; Elkady H; Metwaly AM; Hassan SM; El-Agrody AM Bioorg Chem; 2024 Apr; 145():107157. PubMed ID: 38340473 [TBL] [Abstract][Full Text] [Related]
32. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739 [TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway. Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents. Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750 [TBL] [Abstract][Full Text] [Related]
36. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081 [TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
38. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity. El-Dash Y; Khalil NA; Ahmed EM; Hassanin SO; Gowifel AMH; Hassan MSA Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300250. PubMed ID: 37792247 [TBL] [Abstract][Full Text] [Related]
39. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]